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Sweat chloride concenkations are higher in IRT-positive newborns 
with one CFTR mutation than in other IRT-positive neonates 
G.F. Met  gni, F. Festini, G. Taccetti, T. Repett o, F. Chiarell i  
Cf Center of Tuscany, Floretwe, Italy 
A neonatal screening program for CF has been carried out since 1991 by the CF 
Center of Florence on all the newborns of Tuscany, Italy, using a IRT/Lactase/IRT 
protc~ol. 
From Feb. 20, 2C~)1 to May 20, 2003, all the blood spots of children who resulted 
IRT positive were tested for CFFR mutations (32 mutations, PCR OLA assay mad 
DGGE analysis). 
A im:  to investigate i f difference xists ha sweat chloride concentrations between 
non CF neonates who were IRT positive and carriers of a CFFR mutation, and those 
who were IRT positive mad negative to the genetic test. 
During the period, 64,114 newborns were screened for CF and 744 resulted IRT 
positive and were not affected by CF. Among them, 48 (6.4%) resulted cmriers of a 
CFTR mutation (DF508 carriers n 32, 66.6%). O1" 744 non CF, IRT positive 
children, according to the screening pr at c~ol 161 underwent a sweat est (Gibson & 
Cook). 
The min imum quantity of sweat collected was 60 mg (sweat rate 1.05 g/m2/min);  
the mean age at sweat test was 65 days, SD 42. Of  these 161 neonates, 26 (16.1%) 
resulted to be carriers of a CFFR mutation (DF508 carriers n 18) and 135 were 
negative to genetic testing. 
The mean sweat chloride concentration of CFFR mutation carriers was 16.4 mEq/L, 
SD 8.1 (median 14, range 8 41), whereas that of newborns negative to genetic test 
was 13.5 mEq/L, SD 5.1 (median 13, range 4 34) p~).02, difference 2.9 mEq/L, 
CI95%: 0.5 5.2. 
In our population we found a statistically significant difference between the mean 
sweat chloride concentration of non CF, IRT positive newborns with a CFTR 
mutation and that of those negative to genetic test. 
These findings might be interpreted as a possible result of the mutated CFTR 
protein action on the sweat chloride concentration ha the cmrier newborns. 
Telethon Italy, Grant ECI208/2000 
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Congenital bilateral absence of the vas deferens (CBAVD): when does 
it lead to cystic fibrosis (CF) diagnosis? 
G. Pizzamigl io 1,M.A. Monti  1, L. B arbelt a1, M. Seia ~ 
~CF Adult Center; Internal Medicine, ICP, Milan, Italy; 2Molecular Genetics Lab, 
ICP, Milan, Italy. 
Introduction: male infertility, particularly CEAVD is a typical f inding in classical 
CF. Atypical CF may presents as isolated CEAVD ha patients (pts) with two CF 
mutations and positive or border l ine sweat test. CFTR dysfunction is often 
associated with the etiopathogenesis of CEAVD. A im of this study is to investigate 
the relationship between CEAVD and CF diagnosis. Methods: 13 pts with CEAVD 
and one/two CF IR  mutations or polymorphism were referred to our CF center. 
Results: mean age was 32.5 yrs, min  max 26 39 ; cl inical history was not relevant in 
all but 5 pts (respiratory symptoms). 8/13 pts had been smokers in their life. Genetic 
assessment showed: a severe plus a mild mutation in 8/13 cases, a severe mutation 
plus poli T 5~ or 5/9 polymorphism in 4 pts and po l iT  5/9 alone in one pt. Sweat 
test (CI mean value 69.9 mEq/l, min max 46.2 101) was positive ha 9 pts, border 
l ine ha 4 pts. Mean FEV lwas  99.4%, min max 84 116. Chest X~ay demonstrated 
bronchial markings in 9/13 pts, was normal ha 4/13 pts. Sputum culture was positive 
for Pseudomonas aemginosa ha 4/13 pts, Stenotrophomonas maltophil ia ha 1 pt, 
St aphilc~c~cus aureus ha 1 pt, negative in 7 pts. Mean EMI  was 24.3 min max 20 
30. Sinusopathy was demonstrated ha 8/13 pts, no other CF related disease was 
detected at diagnosis. In co~wIusion a classical form of CF was confirmed ha 4 pts, 
in 7 pts a diagnosis of atypical CF was performed mad CF was temporari ly excluded 
in 2 pts. No pt presented a relevant respirator3, disease despite individual f indings 
of infection, chest X ray, anmmaeslic data. The prognosis of these pts is not 
foreseeable and they need to be monitored for the development of CF 
complications; treatment eeds to be individualized. 
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Diagnosis CF?: Funcfional chloride secretion, complete CFTR 
screening, sequencing and transcript analysis in patients with 
inconclusive sweat test and CFTR mutation screening 
N. Derichs 1, J. Sanz 9, C. Rokahr 1, T. van Kaenel 9, U. Laabs 1, B. Siebert 1, B. 
Tf immler 1, S. Gallati 2, M. Ba l lmann 1 
~Departrnent of Pediatric PuImmu~logy a~u] CF Research Group, Medical School 
Hannover; Germany; 2Division of Human Genetics, ChiMren's University-Hospital, 
Bern, Switzerland 
Exclusion of mild or monos3,mptomatic CF often is difficult ha condition of 
inconclusive sweat est and CFTR mutation screening. Functional analysis of CFTR 
chloride secretion by both nasal potential difference (nPD) mad intestinal current 
measurement (ICM) has been proven to be of high sensitivity and specificity. This 
study aimed to cat,  elate these methods with an extended genetic analysis ha a 
preselected patient cohort with borderline diagnostic features, and to establish a 
most informative pr ccedure. 
From n 164 patients with mild CF phenotype, inconclusive sweat est and/or CFTR 
mutation screening, n 115 were investigated by ICM and n~49 by both nPD mad 
ICM. Individuals wi th borderl ine/pathological  sweat chloride or low 
normal/pathological chloride secretory responses (n 30) were included into 
extended genetic evaluation (complete CFTR mutation screening exon 1 27/intron 
11+19 by SSCP HD analysis, sequencing and transcript analysis). 
In n~ patients the results of ICM and/or nPD were CF typical. No correlation with 
absolute sweat chloride concentrations was seen. Electrophysiological result 
interpretation was confirmed by the extended genetic investigation, revealing two 
pathogenic CFTR mutations only ha the patients classified as CF upon ICM/nPD. 
Chloride secretory phenotypes were consistent with the extended genetic analysis ha 
this highly informative patient cohort. ICM/nPD evaluation of patients with 
borderline phenotype aids in the diagnostic pr c~ess mad should be applied in cases 
of inconclusive routine tests. 
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p.S1235R : a cysfic fibrosis causing or non-causing mutafion? 
Results from a French Molecular collaborative study 
M. des Georges l, E. Gir odon 2, C. Guilt ard l, F. Chevalier ~, C. Dorche 3, T. Bienvenu 4,
V. Dumur 5, M. Blayau 6, A. Iron 7, H. Mittre 8, D. Feldmann 9 ,M. Claustres 1 
~Laboratoire de Gdndtique Moldculair~, CHU, Montpellier; France, 2Mo~tdor~ 
Crdteil, 3Debrousse-Lyon, 4Cochin-Paris, SCaIrnette-Lille, 6Pontchaillou-Rennes, 
7pelIegrin-Bordeaux, sCldme~weau-Cae~ 9Trousseau-Paris, Fra~we 
More than 1300 different mutations in the CFFR gene, causing or non causing 
disease, have been reported to the CF Consortium. p.S 1235R, initial ly reported in a 
CF patient with a second mutation on the same al lele (p.G628R), has been found at 
a frequency higher than that of many other mutations and its cl inical significance is
not clear. 
The aim of this study is to compare the phenotypes of 57 subjects with p.S 1235R in 
order to classify this sequence anomaly. They were referred for diagnosis of 
classical CF, non classic or atypical phenotypes or carrier screening. The entire 
coding and f lanking regions and six microsatellite markers were analyzed. 8 
patients (3 CF, 4 CBAVD, 1 ICP) and 2 normal individuals were compound 
heter ozygotes for a severe CFFR mutation, p.S 1235R was found to be associated on 
the same al lele with a stop mutation (p.R785X) in 2 CF patients with a severe 
disease and TG13 T5 in the 4 CBAVD patients. The CF patient with a mild 
phenotype, the ICP patient and the normal subjects did not cmry a complex allele. 
Our data suggest that another CFFR mutation may hffluence the pathogenic effect 
of p.S 1235R in severe classical CF or in patients howing pathology closely l inked 
to mutations in the CFFR gene. However, p.S 1235R alone, when combined ha trans 
with a second CF mutation, may be associated with a mild phenotype or with 
absence of cl inical manifestations. 
